This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human 4-1BB Ligand / TNFSF9 Protein, Fc Tag
catalog :
41L-H5257
quantity :
50 ug, 1 mg
price :
350 USD, 2400 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
41L-H5257
product name :
Human 4-1BB Ligand / TNFSF9 Protein, Fc Tag
quantity :
50 ug, 1 mg
price :
350 USD, 2400 USD
quantity & price :
$350/50ug,$2400/1mg (250ug × 4)
target :
4-1BB Ligand
host species :
Human
By Tag :
Fc Tag
Research :
For Research Use Only
Source :
Human 4-1BB Ligand, Fc Tag (41L-H5257) is expressed from human 293 cells (HEK293). It contains AA Ala 50 - Glu 254 (Accession # NP_003802).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human 4-1BB Ligand, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Tumor necrosis factor ligand superfamily member 9 (4-1BBL) is also known as 4-1BB ligand, CD137L or TNFSF9, which is a cytokine that binds to TNFRSF9. 4-1BBL is the high affinity ligand of 4-1BB. 4-1BBL induces the proliferation of activated peripheral blood T-cells. Also, 4-1BBL may have a role in activation-induced cell death (AICD). Furthermore, 4-1BBL may play a role in cognate interactions between T-cells and B-cells/macrophages. As for diseases, 4-1BBL is involved in cancers, infectious diseases and autoimmune diseases.
References :
(1) Won E.Y., et al., 2010, J. Biol. Chem. 285:9202-9210.
(2) Alderson M.R., et al., 1994, Eur. J. Immunol. 24:2219-2227.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments